APA (7th ed.) Citation

Koch, J. C., Leha, A., Bidner, H., Cordts, I., Dorst, J., Günther, R., . . . Lingor, P. (2024). Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): A phase 2, randomised, double-blind, placebo-controlled trial. The lancet, 23(11), . https://doi.org/10.1016/S1474-4422(24)00373-9

Chicago Style (17th ed.) Citation

Koch, Jan Christoph, et al. "Safety, Tolerability, and Efficacy of Fasudil in Amyotrophic Lateral Sclerosis (ROCK-ALS): A Phase 2, Randomised, Double-blind, Placebo-controlled Trial." The Lancet 23, no. 11 (2024). https://doi.org/10.1016/S1474-4422(24)00373-9.

MLA (9th ed.) Citation

Koch, Jan Christoph, et al. "Safety, Tolerability, and Efficacy of Fasudil in Amyotrophic Lateral Sclerosis (ROCK-ALS): A Phase 2, Randomised, Double-blind, Placebo-controlled Trial." The Lancet, vol. 23, no. 11, 2024, https://doi.org/10.1016/S1474-4422(24)00373-9.